Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.
Neurology. 2012 Apr 24;78(17):1346-53
Authors: Holland S, Silberstein SD, Freitag F, Dodick DW,
Argoff C, Ashman E, Quality Standards Subcommittee of the American
Academy of Neurology and the American Headache Society
OBJECTIVE: To provide updated evidence-based recommendations for
the preventive treatment of migraine headache. The clinical question
addressed was: Are nonsteroidal anti-inflammatory drugs (NSAIDs) or
other complementary treatments effective for migraine prevention?
METHODS: The authors analyzed published studies from June 1999
to May 2009 using a structured review process to classify the evidence
relative to the efficacy of various medications for migraine prevention.
RESULTS: The author panel reviewed 284 abstracts, which
ultimately yielded 49 Class I or Class II articles on migraine
prevention; of these 49, 15 were classified as involving nontraditional
therapies, NSAIDs, and other complementary therapies that are reviewed
RECOMMENDATIONS: Petasites (butterbur) is effective for migraine
prevention and should be offered to patients with migraine to reduce
the frequency and severity of migraine attacks (Level A). Fenoprofen,
ibuprofen, ketoprofen, naproxen, naproxen sodium, MIG-99 (feverfew),
magnesium, riboflavin, and subcutaneous histamine are probably effective
for migraine prevention (Level B). Treatments considered possibly
effective are cyproheptadine, Co-Q10, estrogen, mefenamic acid, and
flurbiprofen (Level C). Data are conflicting or inadequate to support or
refute use of aspirin, indomethacin, omega-3, or hyperbaric oxygen for
migraine prevention. Montelukast is established as probably ineffective
for migraine prevention (Level B).
PMID: 22529203 [PubMed - indexed for MEDLINE